… , they have flexibility to robustly degrade a wide variety of … of systemic degradation to be
achieved. However, exploitable … PROTAC AR degrader bavdegalutamide, the PROTAC ER …

… LDK378 and the antiproliferative activity to xenograft tumor … ALK degrader B3 with in vitro
and in vivo anti-cancer activities … of PROTAC BCL-XL degraders as potent anticancer agents …

… -targeting chimera (PROTAC) concept. This work has led to the discovery of potent and
effective SHP2 degraders, exemplified by SHP2-D26. SHP2-D26 achieves DC 50 values of 6.0 …

… for degrading various protein targets (24). For example, our group has 104 developed a
tissue-selective PROTAC for degrading BCL-XL … that PROTAC degrader may achieve 577 long-…

… to selectively degrade target proteins. Recent progress in the … protein degradation are mostly
achieved via biomacromolecules. … and risks of this emerging PROTAC technology in clinical …

… the prevented Bcl-xL degradation … the Bcl-xL degradation caused by the pro-Supra-PROTAC.
In addition, to confirm the capability of the pro-Supra-PROTAC to selectively degrade Bcl-xL…

… (PROTAC) that can selectively degrade BCL-XL via the VHL ubiquitin E3 ligase (20). Our lead
BCL-XL PROTAC, … Second, this particular PROTAC was effective at engaging BCL-XL but …

… Here, we develop a peptide-based PROTAC, which achieves the purpose of degrading
FOXM1 by facilitating the recruitment of E3 ubiquitin to FOXM1. Phage display technology was …

… In the PROTAC process, a heterobifunctional degrader forms a … The majority of PROTAC
discovery and development … molecule to achieve the required degradation potency, selectivity, …

… potent AKT proteolysis targeting chimera (PROTAC) degraders: von Hippel–Lindau (VHL)-recruiting
degrader … substantially at 100 nM and achieved near-complete depletion of T-AKT at …